www.11psb.com_www.11psb.com-【中彩号码】

来源:苹果CEO库克来故宫并且和博物馆院长聊了聊  作者:   发表时间:2019-08-24 12:17:29

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

编辑:www.11psb.com_www.11psb.com-【中彩号码】

未经授权许可,不得转载或镜像
© Copyright © 1997-2017 by xbaishengmen.com all rights reserved

百站百胜: 一周雪上综述:日本黑马造就跳台滑雪最大奇迹 李泽钜:公司的策略一定没有改变努力为资产增值 又一对明星公布恋情了!女方是90后,两人相差20岁 你的垃圾我的宝贝!辽宁旧将砍20分创生涯新高 别把个人隐私不知不觉“喂”给人工智能 鳳山拖吊車與機車碰撞 騎士當場喪命 上海造币律师声明:开国大典1公斤纪念银币为假冒产品 长和:2018年净利润390亿港元同比增11% 清明祭祖燒金紙小心PM2.5空汙損健康 又一起河北井陉卫健局将失独家庭列为扫黑对象 探访江苏盐城爆炸事故核心区:一片狼藉犹如无人区 土耳其油轮救起120名难民却反被劫持要求开往欧洲 婴儿少生病的秘密:吃 赛季报销!赛季没打几场这可是联盟第一中锋 個資疑外洩二胎蟑螂上門?桃市府否認 美总统专机价格接近核航母特朗普被质疑根本没砍价 美国63岁华人男子健身有道七年只吃鸡和鱼肉(图) 特朗普提名的联储候选人被美媒挖出拖欠税款 诺华多发性硬化症重磅药物获美国FDA批准 瑞信CEO去年赚1265万瑞郎为欧洲最赚钱银行高管之… 网曝郑俊英聊天群新名单SJ强仁郑珍云李哲宇在列 王力宏迪拜酒吧展歌喉引主持人惊呼“他是谁” 三大行齐唱好蒙牛乳业午后上升4%创9个月高位 响水官方:涉事化工厂5公里内仅1所幼儿园无学生伤亡 两个主项背靠背比赛怎么办?泳坛小天王困扰已两年 顺风车日订单数跌破200万?限价、合规、合乘次数待解 扬州工地致6死事故涉事3家上市公司回应 脱欧迎来“加时赛”英欧分手要拖到何时? 传昆仑万维考虑出售旗下约会应用Grindr 国足最后1战或派3前锋为求一胜卡帅亲自示范长传 丘成桐院士获“影响世界华人大奖”终身成就奖 嫦娥四号着陆器今晚正常唤醒开展第四月昼工作 曝梅西和阿根廷队一直存在隔阂足协拿他当摇钱树 现代途胜NLine官图全面运动化取向 自助火鍋涮螃蟹,各式小菜吃到飽 外卖小哥深夜送餐发暖心提醒:“还是吃正餐好” 雅芳证实被收购传闻:百年品牌如今失色出售广州工厂难止… 评论:银行柜台销售地方债一举多得 鳳山拖吊車與機車碰撞 騎士當場喪命 易烊千玺首谈学生时代遗憾感慨没有同龄小伙伴 杨千嬅半夜背歌词吓坏老公:以为见到鬼 胡彦斌回应以董事长身份入学:叫胡老师比较温暖 大學個人申請一階六和高中:通過人數比率92.19% 17助5断+抢球迷爆米花!湖人夏天该不该留隆多 特斯拉恢复客户推荐奖励计划 汇丰研究:华润置地目标价升至40.6元维持买入评级 彭于晏30年前旧照曝光锅盖头大眼睛萌翻网友 印尼鹰航与波音接近解决737MAX飞机订单问题 盐城化工厂爆炸进展:消防已救出12名伤员 大和:李宁降至持有评级目标价上调至12元 比亚迪2018年净利润达27.8亿元同比下跌31.6… 中市抽驗165件清明祭祖常見食品2件豆干防腐劑不… 花旗:第一太平目标价降至4元维持买入评级 即将升级做母亲事务所停止发售并下架苍井空作品 欺人太甚?希腊总理座机在本国领空被土战机欺负了 限定剧《切尔诺贝利》首曝预告揭开幕后神秘面纱 两天见效!首款治疗产后抑郁的药物问世 非洲“最性感”肌肉村男性个个肌肉型男 日媒:钓鱼岛若有冲突中国军队或先攻击这两座机场 美国页岩油主产区一年来首跌拖累全美原油产量 科比新书登畅销书排行榜第一!魔幻题材谁不爱 叙利亚讽刺美国:想讨好以色列,何不送它几个州 天猫、京东“扫货”商超谁会笑到最后? 三大德国车企加大中国投资:股比放开后合作仍是关键 领先华尔街Coinbase要做权益分配世界里的新王… 不到半年2起空难埃航空难原因疑与狮航空难一样 美银美林:嘉里物流目标价升至15.2元给予买入评级 1.4亿股民画像来了:理财主要靠炒股炒股主要靠工资 61+7+9三分!MVP锁定?最骚的是他还加练了! 花滑世锦赛短节目陈巍领跑羽生结弦第3金博洋第9 性能出众还省油名爵6新能源Trophy版性能体验 刘銮雄长子小15岁新欢曝光,网友吐槽:父子审美隔了一条… 25岁湖人小伙的照片!让我想起这仨程序员(gif) 蔚来汽车回应“大规模裁员”质疑:纯属捏造 苹果因无法达到其质量标准取消Airpower产品 美陆军重审装备采购计划未来5年可节省300亿美元 响应国家号召上汽通用三大品牌调整售价 全球经济放缓提高了美联储今年降息的预期 苹果大股东巴菲特使用的是一款售价20美元的翻盖手机 中超第3轮转播计划:CCTV5转播两场恒大&鲁能受关… 從胃暖到心裏!嘗一碗地道俄勒岡周打海鮮濃湯 中国神华急跌半成暂最差蓝筹去年少赚近8% 轻资产收入10亿:朗诗剥离不赚钱业务 中信建投:五一假期延长关注张家界+云南旅游 追平魔术师历史第一!可怕的是最佳新秀还不稳 科研人员利用人工智能为癌症患者无创分级 ?媒体评“流浪汉爆红网络”:流浪的大师流量的疯子 提前10场连续6年出局!詹姆斯体会科比末年的痛 斯塔诺:德比将是一场盛会再次面对国安非常平静 金博洋:秘诀是对自己更狠了未来目标再涨10分 百强企业拿地态度趋谨慎拿地金额比重降19.7百分点 北京互金协会:防范以STO等名义进行非法金融活动 金管局再入市承接逾16亿港元 宋茜方就诋毁谩骂内容发声明:谴责网络暴力 传球大师+篮板怪兽!下赛季他将再次联手詹皇 交银国际:三生制药2018年业绩超预期维持买入评级 叶诗文获冠军赛第二金200蛙创个人最佳将成主项 香港医管局为医护人员补打麻疹疫苗持续监察疫情 有才天下猎聘拟9.44亿元收购长沙冉星 多倫多的船酒店,你住過了嗎?住在船上,迎臨海港風情 美国国防部官员:考虑用爱立信或诺基亚技术搭建5G网 乃木坂46崛未央奈写真集《你的风格》第六次再版 习近平为何如此强调思政课?这四篇评论员文章告诉您答案 孟美岐跳《卡路里》超沉醉随音乐舞动十分享受 拉卡拉IPO迷雾:股权转让疑点多神秘PE屡\"高买低… 世锦赛扎吉托娃夺冠成就大满贯梅娃第3陈虹伊第19 嘉年华国际料去年亏损30亿主席所持逾10亿被斩仓 任职新岗2个月卸任他曾是全国著名“反腐先锋” 美海军拟将航母数量增至12艘计划3年建一艘 《都挺好》收官催泪大团圆爆款不靠公式精算 内地民企香港上市潮:存破发可能还争先上市图什么? 汪小菲纪念与大S结婚八周年感慨曾经历风风雨雨 韩德君现身海南三亚的餐厅推测将无缘季后赛 小米扛着一场战役:可能是雷军最好也是最后一次机会 Spotify收购洛杉矶播客公司Parcast两月内… 东阳光药业沙门氏菌罗生门:处罚难产企业提行政复议 鳳山拖吊車與機車碰撞 騎士當場喪命 看武磊不用熬夜!西甲照顾中国球迷改比赛时间 美国这次在联合国安理会上被完全孤立连盟友都反对 埃航失事客机初步调查结果出炉! 谁的板蓝花?62件商标归属成谜正大旗下企业陷纠纷 两天见效!首款治疗产后抑郁的药物问世 重庆银行2018年营业收入同比增长6.1%至106.3… 直击|京东推智能采购平台解决“价格不透明”等问题 美图宣布年中前关闭手机业务后续将由小米负责研发 冠军赛孙杨200自夺冠再创世界最佳汪顺获第三 武陵深处展新颜——湘西贯彻精准扶贫理念的生动实践 直击|微软洪小文:对用户来说,方便和隐私互相冲突 油价调价窗口今开启:或再上涨用油成本继续增加 李宁急升近8%去年多赚近4成 英国55岁妈妈替女儿代孕亲自诞下外孙女 挪威邮轮遇险照片曝光:大角度倾斜一片狼藉(图) 美方近期关于中美谈判的表态上有个现象很有趣 梁静茹空中瑜伽双腿笔直穿紧身衣锻炼秀纤细身材 郭鹤立任甘肃临夏州委书记杨元忠另有任用 响水爆炸事故现场搜救工作正式结束搜救出164人 任副省长第二天王永康清理楼道环境 2000三分!50+三双!里程碑之夜“登”火辉煌 响水爆炸遇难者七日祭当地举行集体哀悼活动(图) 上汽通用3品牌39款车型同步调价最高降2.5万元 羽生结弦失误后感慨:今天头脑一片空白 跨界就真的好用吗,体验哈弗F7X 松重丰出道34年首次主演电影应对日本少子化现象 48胜都能成为乐透球队!狂野西部究竟有多恐怖? 泰晤士报:英国内阁公开叛变策划威胁特里莎·梅下台 北京多区发布大风蓝色预警阵风可达7级左右 华为P30背后的较量:OPPO、vivo、诺基亚等拼拍… 卫健委:医疗机构遇患者投诉不得推诿搪塞 贾跃亭卖楼“续命”:法拉第美国总部被出售 巴尔向国会递交穆勒调查结论:无证据显示川普在大选中“通… 评论:银行柜台销售地方债一举多得 体验波音新系统后,这家美国公司决定延长禁飞期限 柯洁首次回应免试上清华:希望圆自己刻苦学习梦想 郭广昌:复星对2019中国市场持乐观态度机会足够多 特斯拉CEO马斯克与SEC下周将对薄公堂 2017东非大冒险:前往马赛马拉 广汽丰田将于2020年引入纯电动C-HR车型 “男儿当自强”配乐下孙杨晋级对年轻队员有话说 库克:感谢中国打开了大门我们的未来密不可分 历史前二控卫想来湖人!泰伦卢再一次成为焦点 河北湖北均进行首例地市媒体整合:党报电视台合并 硅谷的IPO百万富翁们会怎么花钱 英国跳水神童戴利跃升超级奶爸世锦赛盼再争金 张震岳回击酒吧检举坚持立场决不妥协 蔡英文“出访”闹乌龙多名随行记者被瑙鲁国会轰出场外 瓜帅宣言:为四冠王搏一把!穆帅弗爵曾接近神迹 年度最佳杂耍进球!湖人最恨之人秀神操作-gif 前领导哄骗14名员工开卡贷款数百万全部用于赌博 奥迪e-tron系列将打造纯电中级轿车 闲鱼上卖仿制茅台阿里\"灭绝师太\":抽查发现会关… 1图流|回忆杀!打败美国梦之队的黄金一代重聚 剑桥承认高考成绩网友:算上运动会成绩也不够 黄晓明承认自己某些时候演技不好听到质疑会心痛 味千经营溢利降23%CFO涉嫌挪用资金 种草时代下京东也要培养自己的带货红人 俄拟研发无人版T-90坦克较美欧同类武器技高一筹 路透社:索尼将关闭在北京智能手机工厂转移至泰国 詹姆斯复刻Theblock!半场起步大追帽拉塞尔 “超级太阳风暴”要来了,你准备好了吗? 魔兽霍华德确认赛季报销!本赛季他只打了9场 走访越南足球的崇明岛PVF学院贡献8名国奥球员 亚美尼亚诺亚方舟传媒蒂乌扬:媒体应该加深合作 沈腾颜值打败蔡徐坤刘昊然,沈腾:拒绝领奖! 中日职业拳击对抗只有四届?中国诸拳王都曾获益 原訂高市毒防局長楊華中改變主意不到任 传华为将进军智能显示屏市场不同于传统电视机 这次是真的?周杰伦透露今年一定会有新专辑 3·15遭点名家电售后市场如何破局? 特殊高中录取分数线公布史岱文森最高 印尼渔民捞到中国“海翼”水下无人滑翔机(图) 葱桶堪称中国体坛头号组合风云人物”无冕之王“ 豪华邮轮“维京天空”号因何涉险?挪威官方展开调查 13中12在场净胜30分!季后赛没来死神先来了 《拆弹专家2》正式开机刘德华倪妮刘青云等现身 股市跌势如滚雪球日经225指数创下今年最大单日跌幅 华为2018年运营商业务下滑1.3%轮值董事长郭平回… 云集:“她经济”掘金者